Patient survival after acute voluntary poisoning with a huge dose of oxcarbazepine and olanzapine - Kalogera V, Galopoulos D, Eleftheriotis G, Meimeti E, Malios I, Marathonitis G, Loupa C.
INTRODUCTION: Oxcarbazepine is a carbamazepine pre-drug with less drug interactions. Its adverse effects, including hyponatremia, somnolence and ataxia, are dose dependent. Olanzapine is an atypical antipsychotic drug most commonly used to manage psychoses... (Source: SafetyLit)
Source: SafetyLit - December 8, 2018 Category: International Medicine & Public Health Tags: Poisoning Source Type: news

Novel Schizophrenia Drug Shows'Favorable Weight Profile'Novel Schizophrenia Drug Shows'Favorable Weight Profile '
In topline results from the phase 3 ENLIGHTEN-2 trial, patients with schizophrenia who received olanzapine/samidorphan showed significant less weight gain than those who received olanzapine alone.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 3, 2018 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Novel Antipsychotic Curbed Weight Gain, Drugmaker Says
(MedPage Today) -- Olanzapine/samidorphan showed less weight gain versus olanzapine alone in phase III trial (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - November 30, 2018 Category: Primary Care Source Type: news

Alkermes shares dip despite 'positive' trial results from schizophrenia drug
Alkermes, one of the state ’s largest drugmakers, announced the results of a late-stage trial of a schizophrenia drug Thursday it calls "positive," but investors appear to have doubts about the drug’s effect on patients’ weight. Alkermes (Nasdaq: ALKS) has been developing a daily schizophrenia drug, called ALKS 3831, t hat it hopes will compete with Zyprexa, a drug by Eli Lilly (NYSE: LLY), but cause less weight gain in patients. Results of the Phase 3 clinical trial appeared to show that… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 29, 2018 Category: Biotechnology Authors: Allison DeAngelis Source Type: news

Alkermes schizophrenia treatment meets main goals in late-stage study
Alkermes Plc's treatment for schizophrenia met the main goals in a late-stage study, with patients not gaining as much weight as those treated with commonly used antipsychotic drug olanzapine, the company said on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - November 29, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Manitoba paramedics 1st in Canada to offer new medication for meth users
The provincial government will permit paramedics to administer olanzapine to agitated people who have used methamphetamine, Health Minister Cameron Friesen announced on Monday. (Source: CBC | Health)
Source: CBC | Health - November 26, 2018 Category: Consumer Health News Tags: News/Canada/Manitoba Source Type: news

No Gain with Antipsych Meds Switch in Schizophrenia
(MedPage Today) -- Similar rates of remission with continued amisulpride and switch to olanzapine (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - August 13, 2018 Category: Primary Care Source Type: news

What We Know About the Effect of Psychotropic Drugs on Migrant Kids
A federal judge on Monday ruled that the government must obtain parental or guardian consent before administering psychotropic drugs—those that can affect the brain or behavior—to migrant children in its care. But plenty of questions still remain about what these drugs do to young brains in the first place. “The benefits or risks of psychotropic medications to brain development are only beginning to be evaluated,” says Dr. Manpreet Singh, director of the Pediatric Mood Disorders Program at Stanford University. “We haven’t actually looked, directly and in systematic ways, at the effects o...
Source: TIME: Health - July 31, 2018 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Drugs healthytime onetime Source Type: news

Antipsychotic Tx Linked to Adiposity Changes in Youths
THURSDAY, June 14, 2018 -- Youth receiving antipsychotic treatment have adverse changes in adiposity and insulin sensitivity, with the greatest fat increases seen with olanzapine, according to a study published online June 13 in JAMA... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 14, 2018 Category: Pharmaceuticals Source Type: news

Some Antipsychotics in Pregnancy May Up Gestational Diabetes Risk
(MedPage Today) -- Elevated risk seen with continuing olanzapine, quetiapine (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 8, 2018 Category: Cardiology Source Type: news

Two Antipsychotics Linked to Risk for Gestational Diabetes Two Antipsychotics Linked to Risk for Gestational Diabetes
Two antipsychotics, quetiapine and olanzapine, have been linked to an increased risk for gestational diabetes in women who continue to take these drugs during pregnancy, new research shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 7, 2018 Category: Consumer Health News Tags: Psychiatry News Source Type: news

The Drugs That Changed Our Minds by Lauren Slater – review
Twenty years after hailing antidepressants in her memoir Prozac Diary, a now jaded, sceptical Lauren Slater revisits the psychopharmacological industry – with uneven resultsInProzac Diary (1998), Lauren Slater wrote powerfully of the way fluoxetine had transformed her previously chaotic life. While the author recorded a handful of negative side-effects – a profound loss of libido, for instance – the reader was left with the sense that Prozac had pieced back together the shards of Slater’s existence. In some ways,The Drugs That Changed Our Minds is a sequel to that book. Slater is now in her mid-50s,...
Source: Guardian Unlimited Science - April 1, 2018 Category: Science Authors: Alex Preston Tags: Autobiography and memoir Science and nature Books Medical research Depression Society Culture Source Type: news

Lowering Antipsychotic Dose Can Improve Symptoms in Schizophrenia Lowering Antipsychotic Dose Can Improve Symptoms in Schizophrenia
Reducing the dose of risperidone and olanzapine can improve cognitive function and negative symptoms in patients with stable schizophrenia, new research from China suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 27, 2018 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Medicating for mental health
Weight gain and Type 2 diabetes are potential side effects in people taking a common medication to treat mental illness. Now a new University of Guelph study has revealed that a single bout of intense exercise performed right before taking a dose of olanzapine could be a way to prevent these side effects. (Source: World Pharma News)
Source: World Pharma News - March 21, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Medicating for mental health
(University of Guelph) University of Guelph researchers found evidence that a single bout of exhaustive exercise protects against acute olanzapine-induced hyperglycemia. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 21, 2018 Category: International Medicine & Public Health Source Type: news

FDA Drug Safety Communication: FDA review of study sheds light on two deaths associated with the injectable schizophrenia drug Zyprexa Relprevv (olanzapine pamoate)
[03-23-2015] The U.S. Food and Drug Administration (FDA) has concluded a review of a study undertaken to determine the cause of elevated levels of the injectable schizophrenia drug Zyprexa Relprevv (olanzapine pamoate) in two patients who died. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 11, 2017 Category: Drugs & Pharmacology Source Type: news

Olanzapine Has Lower Benefit-to-Risk Ratio in Less Severe Bipolar I Olanzapine Has Lower Benefit-to-Risk Ratio in Less Severe Bipolar I
Patients with less-severe bipolar I disorder benefit less from olanzapine than do those with more-severe disease, but both groups experience the same side effects, according to a new meta-analysis.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 2, 2017 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Olanzapine and Fluoxetine (Symbyax) Capsules (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - September 25, 2017 Category: Drugs & Pharmacology Source Type: news

Antipsychotic Polypharmacy With Risperidone and Olanzapine Antipsychotic Polypharmacy With Risperidone and Olanzapine
Given high rates of treatment failure for initial therapy of schizophrenia, is combining risperidone and olanzapine an appropriate approach to improve clinical response and limit adverse effects?Medscape Pharmacists (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 8, 2017 Category: Consumer Health News Tags: Pharmacist Ask the Expert Source Type: news

Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
Important developments that are addressed by the current update include the antiemetic efficacy of olanzapine; evidence to expand the use of NK1 receptor antagonists; and increasing interest in cannabinoids. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 2, 2017 Category: Consumer Health News Source Type: news

Antipsychotic Added to ASCO Antiemetic Guide
(MedPage Today) -- Olanzapine plus standard three-drug regimen (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - August 1, 2017 Category: Hematology Source Type: news

2016 Updated MASCC/ESMO consensus recommendations: Management of nausea and vomiting in advanced cancer
The aim of this paper was to develop a set of evidence-based guidelines for the management of different syndromes related to nausea and vomiting in advanced cancer. The authors found that the level of evidence in most studies is low, but conclude that the drug of choice is metoclopramide, with alternative options including haloperidol, levomepromazine, or olanzapine. For bowel obstruction, the recommendation is to use octreotide given alongside an antiemetic (haloperidol) and where octreotide is not an option to use an anticholinergic antisecretory agent. For opioid-induced nausea and vomiting, no recommendation could be m...
Source: Current Awareness Service for Health (CASH) - April 25, 2017 Category: Consumer Health News Source Type: news

Antipsychotic adjunctive therapy to mood stabiliser should be continued for 6months after remission of a manic episode
One hundred and seventy-eight patients from academic centres in Canada and Brazil with bipolar I disorder and aged ≥17 years, who recently remitted from an acute manic or mixed episode with a combination of mood stabiliser (lithium or valproate) and atypical antipsychotic (risperidone or olanzapine) were randomised to one of the three following groups: (1) discontinue risperidone or olanzapine over 2 weeks beg inning on the day of randomisation and receive placebo substitution for the remaining 50 weeks; (2) receive risperidone or olanzapine for 24 weeks, followed by tapering and discontinuation of the antipsychotic ove...
Source: Current Awareness Service for Health (CASH) - March 16, 2017 Category: Consumer Health News Source Type: news

Delpor Awarded NIH Grant for 3-month Olanzapine Implant for the...
The NIMH funds Delpor’s efforts to utilize its PROZOR™ technology in developing a matchstick-size subcutaneous implant device capable of delivering olanzapine for 3 months through passive diffusion....(PRWeb February 24, 2017)Read the full story at http://www.prweb.com/releases/2017/02/prweb14088705.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 24, 2017 Category: Pharmaceuticals Source Type: news

Symbyax (Olanzapine and fluoxetine) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 23, 2017 Category: Drugs & Pharmacology Source Type: news

Patient with 108-Degree Fever Shows Seriousness of Early Recognition & Treatment of Hyperthermia
Medic 35 is dispatched to a local subdivision for an obese 62-year-old woman with syncope. The responding unit is a fire-based ALS unit staffed by two paramedics. Patient Assessment It's approximately 2:30 p.m., with outside temperatures reaching 95 degrees F and the humidity is at 65%.The patient is lying in the grass next to a picnic blanket and paper plates with half eaten sandwiches. Her husband crouches over her. He says his wife started to complain she felt unwell, and then passed out. Upon evaluation, she's unresponsive to sternal rub. Her airway is patent. Her breaths are rapid and shallow with rales bilaterally. H...
Source: JEMS Patient Care - November 1, 2016 Category: Emergency Medicine Authors: Christine M. Brent, MD Tags: Patient Care Source Type: news

Zyprexa, Zyprexa Zydis (Olanzapine) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 8, 2016 Category: Drugs & Pharmacology Source Type: news

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting
This study is highlighted by DynaMed Plus as a Practice Changing Update. It concludes that the addition of olanzapine 10 mg to 3-drug antiemetic regimen may reduce nausea in patients receiving highly emetogenic chemotherapy. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 22, 2016 Category: Consumer Health News Source Type: news

Sanford Health trial finds new treatment to stop vomiting in chemotherapy
A clinical researched co-authored by Sanford Health oncologist and cancer researcher Steven Powell has found that the drug olanzapine has potential to reduce chemotherapy-induced side effects such as nausea and vomiting. (Source: Drug Development Technology)
Source: Drug Development Technology - July 20, 2016 Category: Pharmaceuticals Source Type: news

Olanzapine Prevents Chemo-Induced Nausea
Adding the antipsychotic drug olanzapine to a standard antiemetic regimen significantly improved prevention of nausea caused by emetogenic chemotherapy. (Source: CancerNetwork)
Source: CancerNetwork - July 16, 2016 Category: Cancer & Oncology Authors: Anna Azvolinsky Tags: Nausea and Vomiting News Source Type: news

Zyprexa Prevents Chemo Nausea (CME/CE)
(MedPage Today) -- Randomized trial findings support previous studies (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - July 15, 2016 Category: Gastroenterology Source Type: news

Olanzapine for Prevention of Chemo-induced Nausea and VomitingOlanzapine for Prevention of Chemo-induced Nausea and Vomiting
Adding the antipsychotic to standard antiemetic therapy appears to greatly reduce vomiting and nausea in patients receiving highly emetogenic chemotherapy. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 13, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Olanzapine 'Really Makes a Difference' in CINVOlanzapine 'Really Makes a Difference' in CINV
Adding the antipsychotic to standard antiemetic therapy appears to greatly reduce vomiting and nausea in patients receiving highly emetogenic chemotherapy. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 13, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Antipsychotic drug also relieves nausea from cancer chemotherapy
(Reuters Health) - Adding the cheap antipsychotic drug olanzapine to conventional anti-vomiting medicine can help prevent nausea in cancer patients, according to a new test of 380 volunteers. (Source: Reuters: Health)
Source: Reuters: Health - July 13, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

La FDA advierte de reacciones de la piel poco comunes, pero graves con el uso del psicofármaco olanzapina (Zyprexa, Zyprexa Zydis, Zyprexa Relprevv y Symbyax)
[05-10-2016] La Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) advierte que el fármaco antipsicótico olanzapina puede causar una reacción cutánea poco común, pero grave, que puede avanzar y afectar otras partes del cuerpo. Estamos añadiendo una nueva advertencia a la etiqueta de información farmacológica de todos los productos que contienen olanzapina, la cual describe esta grave afección conocida como síndrome de hipersensibilidad a medicamentos con eosinofilia y síntomas sisté...
Source: FDA Center for Drug Evaluation and Research - What's New - June 7, 2016 Category: Drugs & Pharmacology Source Type: news

FDA: Olanzapine can cause serious skin reaction
Olanzapine can cause a rare but serious skin reaction that can affect other parts of the body, according to a Food and Drug Administration safety alert released May 10. The condition linked to all products containing the second-generation antipsychotic is called Drug Reaction with Eosinophilia and... (Source: Skin and Allergy News)
Source: Skin and Allergy News - May 11, 2016 Category: Dermatology Source Type: news

FDA: Olanzapine can cause serious skin reaction
Olanzapine can cause a rare but serious skin reaction that can affect other parts of the body, according to a Food and Drug Administration safety alert released May 10. The condition linked to all... (Source: Family Practice News)
Source: Family Practice News - May 11, 2016 Category: Primary Care Source Type: news

FDA Warns of Serious Skin Reaction with Antipsychotic Olanzapine (FREE)
By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM The atypical antipsychotic olanzapine (Zyprexa and others) can cause a serious skin reaction known as drug reaction … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 10, 2016 Category: Primary Care Source Type: news

FDA Drug Safety Communication: FDA warns about rare but serious skin reactions with mental health drug olanzapine (Zyprexa, Zyprexa Zydis, Zyprexa Relprevv, and Symbyax)
[05-09-2016] The U.S. Food and Drug Administration (FDA) is warning that the antipsychotic drug olanzapine can cause a rare but serious skin reaction that can progress to affect other parts of the body. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 10, 2016 Category: Drugs & Pharmacology Source Type: news

FDA Warns of Skin Reaction With Olanzapine
(MedPage Today) -- Zyprexa and Symbyax among products to get warning label (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - May 10, 2016 Category: Primary Care Source Type: news

Olanzapine Linked to Rare but Serious Skin Reaction, FDA WarnsOlanzapine Linked to Rare but Serious Skin Reaction, FDA Warns
The US Food and Drug Administration is warning that the antipsychotic olanzapine has been linked to a rare but potentially life-threatening skin condition. News Alerts (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 10, 2016 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news

A Major Advance Against Chemotherapy's Most Feared Side EffectA Major Advance Against Chemotherapy's Most Feared Side Effect
Dr Mark Kris discusses a study showing that olanzapine is safe and effective for chemotherapy-induced nausea and emesis. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 14, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

The Truth About Gay Men and Depression
It's time to reveal the truth and I'm just going to say it: gay men and depression coexist. Dark, unfathomable, or uneasy, it's just the truth. I realized I was depressed when I was 12 years old. My parents had divorced, I had trouble making friends at school and my mood felt as heavy as the fog that lays over the city of San Francisco where I grew up. I didn't want to get out of bed and life seemed entirely different than the happy childhood I once knew. Life before depression was idealistic. I enjoyed creative arts and running. I also had big dreams to become an actor in New York City. My friends knew me as the outgoing,...
Source: Healthy Living - The Huffington Post - March 17, 2016 Category: Consumer Health News Source Type: news

Acute poisoning with dapsone and olanzapine: severe methemoglobinemia and coma with a favourable outcome - Iliev YT, Zagorov MY, Grudeva-Popova JG.
Dapsone is a drug commonly used in the treatment of leprosy. In Europe it is rarely prescribed, mostly for the treatment of skin diseases such as dermatitis herpetiformis. Poisoning with dapsone is rare and reports of such cases are of interest for toxicol... (Source: SafetyLit)
Source: SafetyLit - March 11, 2016 Category: Global & Universal Tags: Home and Consumer Product Safety Source Type: news

Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following resperidone and olanzapine dose reduction
The use of lower doses of antipsychotics is recommended by experts in the treatment of older patients with schizophrenia, with the literature suggesting that older age is related to greater antipsychotic sensitivity.1 To date, three randomised controlled trials have examined the effects of olanzapine and risperidone dose reduction on clinical outcome in schizophrenia with inconsistent results.2–4 However, this topic has not been addressed specifically in older patients with schizophrenia, nor has the relationship between decreased dopamine D receptor occupancy and cl...
Source: Current Awareness Service for Health (CASH) - March 3, 2016 Category: Consumer Health News Source Type: news

Zyprexa: Also a Pain Med?
(MedPage Today) -- Meta-analysis suggests analgesic effect for antipsychotic drug (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - February 22, 2016 Category: Psychiatry Source Type: news

Adding an Antipsychotic Helps Treat PainAdding an Antipsychotic Helps Treat Pain
A literature review finds that the atypical antipsychotic olanzapine has the most evidence supporting its use in various pain syndromes. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - February 19, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Understanding & Giving Support to Someone with Schizophrenia
What comes to mind when the word schizophrenia is spoken? Likely images of a bedraggled man or woman, with wild hair and tattered clothing, chatting away with someone that you can’t see, as they amble down a city street. You might actually cross the street to avoid him or her, so as not to get caught up in their delusion. The Diagnostic and Statistical Manual of Mental Disorders (DSM-V) describes the condition as “characterized by delusions, hallucinations, disorganized speech and behavior, and other symptoms that cause social or occupational dysfunction. For a diagnosis, symptoms must have been present for six...
Source: Psych Central - February 1, 2016 Category: Psychiatry Authors: Edie Weinstein, MSW, LSW Tags: Antipsychotics Atypical Antipsychotics Caregivers Disorders Family General Medications Psychology Psychotherapy Schizophrenia Treatment American Psychiatric Association Delusion Delusional disorder Diagnostic And Statistical Ma Source Type: news

Comunicado de la FDA sobre la seguridad de los medicamentos: La FDA investiga dos muertes tras inyección con antipsicótico de larga duración Zyprexa Relprevv (pamoato de olanzapina)
El 18 de junio, 2013, La Administración de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) está investigando la inexplicable muerte de dos pacientes que recibieron una inyección intramuscular del medicamento antipsicótico Zyprexa Relprevv (pamoato de olanzapina). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 19, 2016 Category: Drugs & Pharmacology Source Type: news

Transforming Pharmaceutical Manufacturing: Benefits and Challenges
Guest Editor(s) Robin Bogner and Ajaz Hussain Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine loaded solid lipid nanoparticles Author(s) K. Vivek Harivardhan Reddy Ramachandra S. R. Murthy (Source: AAPS Publications)
Source: AAPS Publications - August 19, 2015 Category: Drugs & Pharmacology Source Type: news